Razorfish: Mayer De...
Health Care: Drugs
SciClone Pharmaceuticals (SCLN: NASDAQ)
$4.85 0.02 | 0.41%
05/20/13 - 04:00 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 84.23M | 66.65M | 53.02M | 29.69M |
| Receivables | 38.11M | 42.23M | 30.67M | 21.39M |
| Inventories | 10.42M | 8.81M | 7.08M | 10.15M |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 137.33M | 121.07M | 95.95M | 64.46M |
| Property, Plant & Equipment, Gross | 3.90M | 2.90M | 2.33M | 2.27M |
| Accumulated Depreciation & Depletion | 2.53M | 1.92M | 1.74M | 1.50M |
| Property, Plant & Equipment, Net | 1.38M | 984.00K | 588.00K | 771.00K |
| Intangibles | 0.00 | 45.18M | 53.00K | 0.00 |
| Other Non-Current Assets | 683.00K | 1.11M | 1.22M | 1.66M |
| Total Non-Current Assets | 36.74M | 79.26M | 1.86M | 2.44M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 174.07M | 200.33M | 97.81M | 66.90M |
| Accounts Payable | 7.79M | 5.59M | 3.88M | 2.34M |
| Short Term Debt | 1.44M | 2.50M | 0.00 | 0.00 |
| Other Current Liabilities | 4.41M | 3.27M | 0.00 | 0.00 |
| Total Current Liabilities | 30.81M | 25.28M | 12.13M | 8.53M |
| Long Term Debt | 0.00 | 0.00 | 2.50M | 0.00 |
| Deferred Income Taxes | 0.00 | 8.72M | 0.00 | 0.00 |
| Other Non-Current Liabilities | 237.00K | 15.87M | 990.00K | 979.00K |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 237.00K | 24.58M | 3.49M | 979.00K |
| Total Liabilities | 31.05M | 49.87M | 15.62M | 9.51M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 143.02M | 150.46M | 82.19M | 57.39M |
| Common Par | 54.00K | 58.00K | 48.00K | 47.00K |
| Additional Paid In Capital | 274.39M | 266.91M | 225.90M | 222.23M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -134.41M | -118.85M | -143.82M | -164.90M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 2.99M | 2.34M | 67.00K | 22.00K |
| Total Capitalization | 143.02M | 150.46M | 84.69M | 57.39M |
| Total Equity | 143.02M | 150.46M | 82.19M | 57.39M |
| Total Liabilities & Stock Equity | 174.07M | 200.33M | 97.81M | 66.90M |
| Total Common Shares Outstanding | 54.48M | 57.85M | 48.01M | 47.22M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 56.64M | 55.11M | 47.62M | 46.57M |
| Diluted Weighted Shares Outstanding | 58.48M | 57.39M | 49.41M | 47.40M |
| Number of Employees | 870 | 875 | 261 | 223 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with SCLN
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorTop-Rated Biotechnology Stocks
- UserDivFive
- Contributor10 Pharma Stocks With 100% ...
- UserPicking Winners
- UserMicroCap Biotech/Pharma Sto...
- Userbiotech
- UserDaktowilly Portfolio 1
Latest SCLN Headlines from TheStreet
- Healthcare Sector: High Quality Stocks At A Great Value 03.18.13 | 02:03 pm
- 4 Stocks Under $10 Moving Higher 02.26.13 | 02:02 pm
- Stocks Under $5: Discount Drug Name
11.29.12 | 06:11 am - 9 Stocks On Winning Streaks With Significant Hedge Fund Buying 10.16.12 | 04:10 pm
- 3 Stocks Under $10 Making Big Moves 09.18.12 | 02:09 pm
- 3 Biotech Stocks Under $10 Surging Higher 08.09.12 | 01:08 pm
- SciClone Rises On Unusually High Volume (SCLN) 06.22.12 | 04:06 pm
- SciClone Stock Hits New 52-Week High (SCLN) 06.11.12 | 12:06 pm
- SciClone Stock Gaps Up On Today's Open (SCLN) 03.14.12 | 09:03 am
- SciClone Reaches New 52-Week High (SCLN) 07.14.11 | 10:07 am
Press Releases for SCLN
- Kahn Swick & Foti, LLC Announce Continuing Investigation Into SciClone Pharmaceuticals, Inc. – Firm Appointed Co-lead Counsel In Securities Class Action – SCLN - Business Wire 11.02.10 | 06:11 pm
- Lieff Cabraser Heimann & Bernstein, LLP Announces Class Action Lawsuits Against SciClone Pharmaceuticals, Inc. - Business Wire 09.23.10 | 10:09 am
- Ryan & Maniskas, LLP Announces Class Action Lawsuit Against SciClone Pharmaceuticals, Inc. - Business Wire 08.20.10 | 07:08 pm
- Kendall Law Group Investigates SciClone Pharmaceuticals, Inc. For Shareholders - Business Wire 08.20.10 | 01:08 pm
- Robbins Umeda LLP Announces Investigation Of SciClone Pharmaceuticals, Inc. - Business Wire 08.12.10 | 07:08 pm
- Finkelstein Thompson LLP Announces Investigation Of SciClone Pharmaceuticals, Inc. - Business Wire 08.11.10 | 04:08 pm
- Goldfarb Branham LLP Investigating SciClone Pharmaceuticals For Investors - Business Wire 08.11.10 | 12:08 pm
- Law Offices Of Howard G. Smith Announces Investigation On Behalf Of Shareholders Of SciClone Pharmaceuticals, Inc. - Business Wire 08.10.10 | 08:08 pm
- Levi & Korsinsky, LLP Investigates SciClone Pharmaceuticals, Inc. - Business Wire 08.10.10 | 08:08 pm
- Roy Jacobs & Associates Investigating SciClone Pharmaceuticals, Inc. For Possible Securities Law Violations ("SCLN") - Business Wire 08.10.10 | 05:08 pm
Partner Headlines for SCLN
- SciClone Pharmaceuticals Earnings: Here’s Why Shares are Down Now - Wall St. Cheat Sheet 04.01.13 | 06:04 am
- SciClone Pharmaceuticals Earnings: Here’s Why Shares are Down Now - Wall St. Cheat Sheet 04.01.13 | 06:04 am
- Weekly CFO Sells Highlight: V, SCLN, VR, AMSG - GuruFocus 06.25.12 | 03:06 pm
- 2 $4 Stocks With Rapid Sales Growth That Are Heading Higher - Seeking Alpha 01.31.12 | 06:01 am
- Vertex A Steal Based On Blockbuster Hepatitis C Drug Sales - Seeking Alpha 10.28.11 | 06:10 am
- 9 Stocks Trading Under $7 With Monster Upside Potential - Seeking Alpha 06.09.11 | 08:06 am
- SciClone: Novamed Acquisition Helps, But Questions Remain - Seeking Alpha 05.20.11 | 07:05 am
- 19 High Growth Micro Cap Stocks Under $10 - Seeking Alpha 01.23.11 | 07:01 am
- UPDATE 1-SciClone Pharma Q3 EPS beats, raises FY profit view - Reuters 11.08.10 | 05:11 pm
- Healthcare Headlines: Santarus Rallies, Amgen Announces Results - Seeking Alpha 10.06.10 | 08:10 am
